Niagen Bioscience (NAGE)
NASDAQ:NAGE
Want to see NAGE full AI Analyst Report?
Top Page
Niagen Bioscience
(NASDAQ:NAGE)
Select Model
Select Model
Rating:66Neutral
Price Target:
$4.00
▼(-17.36% Downside)
Action:Reiterated
Date:05/09/26
The score is supported primarily by improved financial fundamentals (profitability, strong growth, and a low-leverage balance sheet) and a reasonable earnings-based valuation (P/E ~13.9). This is meaningfully tempered by weak technicals (price below key moving averages and negative MACD) and cash-flow/investment near-term pressure discussed on the earnings call (inventory/timing impacts plus higher operating spend and competitive/regulatory headwinds).
Positive Factors
High Gross Margins & Profitability
Sustained high gross margins and a profitable TTM net margin reflect durable product-level economics and pricing power for NIAGEN/Tru Niagen. This margin base supports reinvestment, R&D and marketing without immediate dilution of returns, improving long-term cash generation potential.
Negative Factors
Cash-Flow Volatility
Operating cash flow has fallen from prior-year levels due to inventory builds and timing of partner orders, creating volatility between accounting profitability and cash realization. Persistent cash-flow swings can constrain reinvestment, raise working-capital needs, and stress cash returns during growth phases.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins & Profitability
Sustained high gross margins and a profitable TTM net margin reflect durable product-level economics and pricing power for NIAGEN/Tru Niagen. This margin base supports reinvestment, R&D and marketing without immediate dilution of returns, improving long-term cash generation potential.
Read all positive factors
Niagen Bioscience (NAGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$290.70M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)13.9
Beta (1Y)0.92
Revenue Growth20.84%
EPS Growth28.10%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding79,644,325
10 Day Avg. Volume609,647
30 Day Avg. Volume1,043,913
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue1.74
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda16.96
Forecast
1Y Price Target
$11.25Price Target Upside132.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.24
Revenue Forecast (FY)$142.63M
Niagen Bioscience Business Overview & Revenue Model
Company Description
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide....
How the Company Makes Money
Niagen Bioscience primarily makes money through (1) direct-to-consumer and retail sales of finished dietary supplement products that feature its NR ingredient (typically sold online and through retail/distribution channels) and (2) business-to-bus...
Niagen Bioscience Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone: solid revenue and net income, strong e-commerce growth, margin stability, a robust cash position, and several strategic wins (USP monograph, new product launches, scientific leadership). Offsetting items include short-term cash flow drag from inventory and timing, higher selling/marketing and G&A investments, channel volatility with some distribution partners, and intensified competition and regulatory uncertainty around NMN which is creating headwinds. Management reaffirmed full-year guidance (10%–15% growth) while electing to invest in marketing and product rollouts to drive future growth.Positive Updates
Revenue and Profitability
Total revenue of $31.5M ($31.1M excluding divested reference standards), representing a 5% year-over-year increase. Net income of $6.3M and diluted EPS of $0.08 vs $0.07 year-ago.
Negative Updates
Moderate Top-Line Pressure from Key Customers
Two customers ordered less this quarter compared to the prior year, contributing to slower overall growth despite e-commerce strength.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Profitability
Total revenue of $31.5M ($31.1M excluding divested reference standards), representing a 5% year-over-year increase. Net income of $6.3M and diluted EPS of $0.08 vs $0.07 year-ago.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 revenue growth guidance of 10–15% year‑over‑year, calling e‑commerce the primary growth engine (Q1 e‑commerce +14% to $19.2M) and new product launches as upside; Q1 results included $31.5M revenue ($31.1M excl. reference standards, +5% YoY excl. divestiture), TRU NIAGEN $22.4M (+4% YoY), NIAGEN ingredient $8.2M (+2%), gross margin 63.5% (up 10 bps), net income $6.3M (EPS $0.08), cash $66.5M, no debt, and working capital ~$82.3M. They stated selling & marketing spend will increase in absolute dollars and as a percentage of sales (Q1 S&M was 30.7% vs 26.6% LY), now expect G&A to rise $3–4M YoY (revised from prior $4–5M), continue a $20M share‑repurchase program (Q1 repurchases $2.4M), anticipate inventory to decline through the year after a $3.6M inventory build and $1.2M net cash used by operations in Q1, and noted partner order timing (e.g., Watsons) may cause quarterly fluctuations but is expected to improve over the year.Niagen Bioscience Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 130.42M | 129.42M | 99.60M | 83.57M | 72.05M | 67.45M |
| Gross Profit | 83.83M | 83.19M | 61.59M | 50.78M | 42.80M | 41.49M |
| EBITDA | 13.37M | 15.75M | 9.21M | -3.89M | -16.74M | -25.45M |
| Net Income | 18.64M | 17.38M | 8.55M | -4.94M | -16.54M | -27.13M |
Balance Sheet | ||||||
| Total Assets | 114.33M | 106.41M | 68.28M | 54.96M | 54.06M | 57.84M |
| Cash, Cash Equivalents and Short-Term Investments | 66.55M | 64.79M | 44.51M | 27.17M | 20.29M | 28.02M |
| Total Debt | 2.58M | 2.82M | 2.65M | 3.28M | 4.26M | 4.70M |
| Total Liabilities | 32.00M | 29.87M | 22.18M | 26.51M | 25.39M | 26.11M |
| Stockholders Equity | 82.33M | 76.53M | 46.09M | 28.46M | 28.67M | 31.73M |
Cash Flow | ||||||
| Free Cash Flow | 4.05M | 13.14M | 11.95M | 6.97M | -15.43M | -24.57M |
| Operating Cash Flow | 4.37M | 13.44M | 12.11M | 7.12M | -15.10M | -24.16M |
| Investing Cash Flow | 4.99M | -292.00K | -143.00K | -143.00K | -334.00K | -409.00K |
| Financing Cash Flow | 1.58M | 6.98M | 5.37M | -90.00K | 7.65M | 36.09M |
Niagen Bioscience Technical Analysis
Neutral
4.84
Price Trends
4.82
Positive
5.62
Negative
7.32
Negative
Market Momentum
-0.04
Negative
56.28
Neutral
75.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Neutral. The current price of 4.84 is above the 20-day moving average (MA) of 4.54, above the 50-day MA of 4.82, and below the 200-day MA of 7.32, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 75.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NAGE.
Niagen Bioscience Risk Analysis
Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Niagen Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $290.70M | 13.95 | 25.38% | ― | 20.84% | 28.10% | |
62 Neutral | $1.29B | -9.10 | -79.12% | ― | 0.86% | 42.65% | |
57 Neutral | $1.21B | -31.13 | -9.44% | ― | 7295.60% | 58.57% | |
56 Neutral | $818.50M | -2.46 | -102.59% | ― | 5.37% | -60.20% | |
53 Neutral | $1.54B | -4.65 | -50.17% | ― | 34.26% | 23.00% | |
52 Neutral | $1.48B | -2.63 | -53.31% | ― | 213.96% | 25.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NAGE
Niagen Bioscience
3.65
-7.28
-66.61%
IOVA
Iovance Biotherapeutics
3.45
1.62
88.52%
KURA
Kura Oncology
9.22
2.98
47.76%
VIR
Vir Biotechnology
8.79
4.15
89.44%
FTRE
Fortrea Holdings Inc.
13.66
9.21
206.97%
SEPN
Septerna, Inc.
26.95
16.98
170.31%
Niagen Bioscience Corporate Events
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Niagen Bioscience Reports Q1 Results, Updates 2026 Outlook
Positive
May 6, 2026
On May 6, 2026, Niagen Bioscience reported first-quarter 2026 net sales of $31.5 million, a 3% increase year over year or 5% excluding its recently divested Analytical Reference Standards and Services segment, with gross margin improving to 63.5% ...
Business Operations and StrategyStock Buyback
Niagen Bioscience Doubles Share Repurchase Authorization to $20M
Positive
Mar 19, 2026
On March 19, 2026, Los Angeles-based Niagen Bioscience, a specialist in NAD+ science and healthy-aging supplements and IV therapies, said its board doubled the size of its share repurchase authorization to $20 million of common stock from the $10 ...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Niagen Bioscience Reports Strong 2025 Results, Strategic Shift
Positive
Mar 4, 2026
Niagen Bioscience reported on March 4, 2026 that 2025 net sales rose 30% year over year to $129.4 million, driven by strong Tru Niagen and Niagen ingredient demand, while gross margin improved to 64.3%. Net income more than doubled to $17.4 millio...
Business Operations and StrategyM&A Transactions
Niagen Bioscience Divests Non-Core Analytical Standards Business
Positive
Feb 26, 2026
On February 24, 2026, Niagen Bioscience’s subsidiaries ChromaDex, Inc. and ChromaDex Analytics, Inc. completed an all-cash sale of substantially all assets of their analytical reference standards and services business to VHG Labs, part of LG...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.